Assess whether the primary endpoint will survive FDA scrutiny (8dad77)

SITUATION After a boxed-warning proposal from the review division, disproportionate reporting signal workbook is what pediatric-plan strategist can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Clinical and Evidence Strategy file.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Disproportionate reporting signal workbook reads as Proceed under protocol once a boxed-warning proposal from the review division is lined up to the same Pharma & Life Sciences population. 2. Disproportionate reporting signal workbook is closer to Pause the pathway after a boxed-warning proposal from the review division; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in disproportionate reporting signal workbook for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study. 4. Disproportionate reporting signal workbook is missing the fact pediatric-plan strategist needs after a boxed-warning proposal from the review division; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Check whether disproportionate reporting signal workbook supports the labeled claim pediatric-plan strategist would keep. 2. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 3. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a boxed-warning proposal from the review division. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a boxed-warning proposal from the review division and write the one fact that would move the primary endpoint will for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a boxed-warning proposal from the review division). The follow-on Clinical and Evidence Strategy action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in disproportionate reporting signal workbook, then the action for pediatric-plan strategist - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Regulatory or exam hook Clinical and Evidence Strategy would cite - Clinical and Evidence Strategy finding in disproportionate reporting signal workbook that a second reviewer can re-perform